MedTrace Logo

Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

NCT07492927 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1700

Last updated 2026-03-25

No results posted yet for this study

Summary

The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.

Conditions

  • Clinically Significant Prostate Cancer

Sponsors & Collaborators

  • Shaanxi Provincial People's Hospital

    collaborator OTHER

  • Weinan Central Hospital

    collaborator OTHER

  • Shaanxi University of Chinese Medicine

    collaborator OTHER

  • LanZhou University

    collaborator OTHER

  • Qinghai University

    collaborator OTHER

  • Ningxia Medical University

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • Yan'an University Affiliated Hospital

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Weijun Qin, MD. · Xijing Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2026-12-31
Completion
2027-06-30

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07492927 on ClinicalTrials.gov